A 114-person randomized trial of GlyNAC, the glycine and N-acetylcysteine combination marketed as an anti‑aging glutathione booster, missed its primary endpoint. Glutathione did not go up in the group as a whole. It did rise in one subgroup, defined after the fact, and that detail matters more than the headline result.
Why GlyNAC got so much attention
Glutathione is a tripeptide the body builds from glycine, cysteine and glutamate. It neutralizes reactive oxygen species and helps limit tissue damage. Glycine and cysteine are non-essential amino acids, but the idea is that demand for glutathione rises with age, and that supplying more of its raw materials could restore it.
GlyNAC pairs glycine with N-acetylcysteine (NAC), a more stable precursor of cysteine. Earlier, smaller studies, notably from a research group at Baylor College of Medicine, generated much of the enthusiasm around the combination as a way to counter age‑related decline. This 2022 paper in Frontiers in Aging is a different kind of test: a larger, placebo‑controlled, dose‑ranging trial run by Nestlé researchers.
What the trial actually did
- Participants: 114 healthy older adults, mean age 65. A reference group of 20 younger adults (mean age 31.7) provided a comparison at baseline.
- Doses: 2.4 g, 4.8 g or 7.2 g per day, versus placebo.
- Ratio: glycine and NAC at 1:1.
- Duration: two weeks.
- Primary endpoint: total glutathione (GSH‑T) in blood.
- Registration: ClinicalTrials.gov NCT05041179.
The older adults really did look more oxidatively stressed
Even though these volunteers were healthy, they differed from the younger reference group at baseline, with all differences at p < 0.0001 except the ratio:
- Malondialdehyde (MDA), a lipid‑damage marker: 0.158 vs. 0.136 µmol/L
- Total cysteine: 314.8 vs. 276 µM
- Oxidized glutathione (GSSG): 174.5 vs. 132.3 µmol/L
- Ratio of reduced to oxidized glutathione (GSH‑F:GSSG): 11.78 vs. 15.26 (p = 0.0018)
This supports the premise that older adults carry a heavier oxidative burden. It does not show that a supplement fixes it.
The null primary result
GlyNAC was safe and well tolerated, but it did not move the main numbers. At the end of the study:
- GSH‑F:GSSG: 12.49 in placebo vs. 12.65 at 7.2 g (p = 0.739)
- Total glutathione: 903.5 mg/L in placebo vs. 959.6 mg/L at 7.2 g (p = 0.278)
The top dose produced a small numerical bump in total glutathione, but it was not statistically distinguishable from placebo. Across healthy older adults as a whole, two weeks of GlyNAC did not measurably raise glutathione.
The one group that did respond
The authors then ran post‑hoc analyses. They isolated people with high oxidative stress (MDA above the median) and low baseline glutathione (GSH‑T below the median). In that subset, those taking the medium and high doses (4.8 g and 7.2 g, pooled) had higher glutathione at the end of the study: 905.4 mg/L vs. 819.7 mg/L for placebo (p = 0.016).
The finding is interesting, but it needs caution:
- It was post‑hoc. The subgroup was defined after the primary result came back null, so it is hypothesis‑generating, not confirmatory.
- Median splits are arbitrary. Slicing a cohort on two variables creates many chances for a chance finding.
- Doses were pooled. The responder result combines the 4.8 g and 7.2 g groups, which says little about a precise dose‑response relationship.
- The subgroups are small. Splitting 114 people across several arms and two median cutoffs leaves few people per cell.
The pattern is biologically plausible, though. If the body is short of glutathione and under oxidative pressure, extra precursors might matter more than in someone whose levels are already adequate.
Limits worth keeping in view
- Two weeks is short. The trial measured blood biomarkers over a brief window. It says nothing about longer‑term effects, and it measured no clinical outcomes such as strength, cognition or disease risk.
- Healthy volunteers only. The results may not apply to people with chronic disease or frailty, who may be the ones with the highest glutathione demand.
- Biomarkers are not outcomes. Higher blood glutathione is a surrogate marker, not proof of better health.
- Industry sponsorship. The authors are largely Nestlé employees, and Nestlé Health Science holds patents and markets products involving glycine and NAC. The trial was conducted with the contract research organization Profil, which received Nestlé funding. That does not invalidate the work, and the null primary result was reported plainly, but readers should know.
Practical takeaways
Who might benefit? If anyone does, the data point to people with high oxidative stress and low glutathione, not healthy older adults in general. This is a signal from a post‑hoc analysis, not an established indication.
Doses tested: 2.4, 4.8 and 7.2 g/day total at a 1:1 glycine‑to‑NAC ratio. Only the 4.8 g and 7.2 g doses showed an effect in the responder subgroup. The abstract does not describe dosing schedules or timing relative to meals, so no timing recommendation can be drawn from it.
Testing: The responder definition depended on measuring MDA and glutathione at baseline. Those are research‑style assays and not typical routine labs, which makes it hard for an individual to know which group they fall into. Taking the supplement blindly is a gamble on the average result, and the average result was null.
Safety: GlyNAC was well tolerated over the two weeks studied. That says little about long‑term use. Anyone with a medical condition or on medication should check with a clinician first.
Bottom line
This trial does not debunk GlyNAC, and it does not validate the hype. It suggests that glutathione is not simply low in everyone who is older, and that precursor supplementation may only help people who are actually depleted. A larger, longer trial that prespecifies the high‑oxidative‑stress, low‑glutathione group, ideally with independent funding, would turn this hint into an answer.